Filing Flows › Guardant Health (GH) › Guidance & outlook
Guardant Health (GH) guidance and outlook
Guardant Health (GH) raised its guidance on Nov 5, 2026: Revenue $1.4B for FY2026; Revenue +38% to +40% for FY2026; Gross margin 65% for FY2026; Operating expenses $1.1B for FY2026. Guardant Health's 10-Q filed Nov 5, 2026 makes 19 forward-looking statements.
Guidance and outlook
Latest guidance
| Metric | Period | Range | Change |
|---|---|---|---|
| Revenue | FY2026 | $1.4B | raised |
| Revenue | FY2026 | +38% to +40% | raised |
| Revenue | FY2026 | +50% | new |
| Revenue | FY2026 | $233M–$238M | new |
| Gross margin | FY2026 | 65% | raised |
| Operating expenses | FY2026 | $1.1B | raised |
| Free cash flow | FY2026 | $205M–$220M | raised |
From the earnings release filed Nov 5, 2026 (8-K on EDGAR).
Forward-looking statements, 10-Q filed Nov 5, 2026
- We also expect to expand into lung cancer screening and multi-cancer detection, or MCD, with our Shield platform.
- We believe there are several important factors that have impacted and that we expect will impact our operating performance and results of operations, including:
- Our oncology and screening revenue is calculated based on our expected cash collections, using the estimated variable consideration.
- If their policies were to change in the future to cover additional cancer indications, we anticipate that our total reimbursement would increase.
- This variability and unpredictability could increase the risk of future revenue reversal and result in our failing to meet any previously publicly stated guidance we may provide.
- As we continue to develop these relationships, we expect to support a growing number of clinical studies globally and continue to have opportunities to offer our services to such customers, primarily including companion diagnostic development and regulatory approval, monitoring and maintenance, GuardantINFORM data services and GuardantConnect referral services .
- The SOLAR study will continue patient enrollment in 2026, and we aim to conclude the SOLAR study by 2031.
- We have expended considerable resources, and expect to increase such expenditures over the next few years, to support our research and development programs with the goal of fueling further innovation.
- A component of our long-term growth strategy is to expand our commercial footprint internationally, and we expect to increase our sales and marketing expense to execute on this strategy.
- Our equity awards, including performance-based restricted stock units, are intended to retain and incentivize employees to lead us to sustained, long-term superior financial and operational performance.
- We expect the costs associated with performing our tests to generally increase in line with the increase in the number of tests we perform, but we expect the cost per test to decrease modestly over time due to the efficiencies we may gain as test volume increases, and from automation and other cost reductions.
- Costs associated with our service agreements and partnership agreements will vary depending on the nature, timing and scope of customer projects.
Guardant Health's latest quarter
Guardant Health, Q3 2026: revenue $361M (+36% year over year), operating margin -36.8%, net loss $124M, operating cash flow −$23.7M. The chart follows the revenue to costs, profit and cash.
Questions
Did Guardant Health raise or lower its guidance?
Guardant Health (GH) raised its guidance on Nov 5, 2026: Revenue $1.4B for FY2026; Revenue +38% to +40% for FY2026; Gross margin 65% for FY2026; Operating expenses $1.1B for FY2026.
What does Guardant Health expect?
We also expect to expand into lung cancer screening and multi-cancer detection, or MCD, with our Shield platform. We believe there are several important factors that have impacted and that we expect will impact our operating performance and results of operations, including: Our oncology and screening revenue is calculated based on our expected cash collections, using the estimated variable consideration.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.